Pro­to­cols: Boom­ing Mod­er­na adds staff, new clin­i­cal pro­gram; Lil­ly boasts of R&D gains

As promised, fast-grow­ing Mod­er­na has moved its sec­ond pro­gram in­to clin­i­cal de­vel­op­ment. The mR­NA spe­cial­ist now has mR­NA 1440 and mR­NA 1851, in­fec­tious dis­ease vac­cine can­di­dates, in ear­ly stage stud­ies. And there are eight more head­ed to the clin­ic lat­er in the year. The busy clin­i­cal agen­da at Mod­er­na comes as the com­pa­ny re­ports a cash cache of 1B and the re­cent ad­di­tion of 120 staffers, boost­ing the to­tal to 440.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER